Brief: Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder
12/05/2026 14:28
May 12 (Reuters) - Clearmind Medicine Inc CMND.O: CLEARMIND MEDICINE REACHES IMPORTANT CLINICAL MILESTONE: 20 PARTICIPANTS NOW TREATED IN ONGOING PHASE I/IIA TRIAL OF CMND-100 FOR ALCOHOL USE DISORDER Source text: ID:nGNX2r8bQW Further company coverage: CMND.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clearmind Medicine
See all newsBrief: Clearmind Advances Dialogue With U.S. Federal Government On Psychedelic Therapies, Submitting Recommendations To FDA
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM